Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn&apos;s Disease: Results From the VISIBLE 2 Randomised Trial

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

Lancet Gastroenterol Hepatol.

Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO

doi: 10.1016/S2468-1253

RECOMMENDED

Inflammatory Bowel Disease

Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis

★ 2 Recommended by Prof. Dr Stephan Vavricka, Faculty Member

J Crohns Colitis.

Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S

doi: 10.1093/ecco-jcc/jjaa027.

Inflammatory Bowel Disease

Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study

Lancet Gastroenterol Hepatol.

Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G

doi: 10.1016/S2468-1253(20)30188-6.

Inflammatory Bowel Disease

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study

J Crohns Colitis

Ferrante M, Feagan BG, Panés J, Baert F, Louis E, Dewit O, Kaser A, Duan WR, Pang Y, Lee WJ, Gustafson D, Liao X, Wallace K, Kalabic J, D'Haens GR

doi: 10.1093/ecco-jcc/jjab093

RECOMMENDED

Inflammatory Bowel Disease

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease

★ 1 Recommended by Prof. Dr Stephan Vavricka, Faculty Member

Gastroenterology.

Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J

doi: 10.1053/j.gastro.2020.01.047.

Further Publications

Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial

Lancet Gastroenterol Hepatol

Hanauer S, Liedert B, Balser S, Brockstedt E, Moschetti V, Schreiber S

doi: 10.1016/S2468-1253(21)00252-1

Inflammatory Bowel Disease

Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3

Inflamm Bowel Dis.

Sands BE, Van Assche G, Tudor D, Akhundova-Unadkat G, Curtis RI, Tan T

doi: 10.1093/ibd/izy384.

Inflammatory Bowel Disease

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis

Gastroenterology.

Sandborn WJ, Baert F, Danese S, Krznarić Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D'Haens G, Vermeire S

doi: 10.1053/j.gastro.

Inflammatory Bowel Disease

Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study

BMC Gastroenterol.

Snowden JA, Hawkey C, Hind D, Swaby L, Mellor K, Emsley R, Mandefield L, Lee E, Badoglio M, Polge E, Labopin M, Gribben J, Pockley AG, Foulds GA, Lobo A, Travis S, Parkes M, Satsangi J, Papaioannou D, Lindsay JO, Autologous Stem Cell Transplantation In Refractory CD - Low Intensity Therapy Evaluation Study Investigators., European Society for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP)

doi: 10.1186/s12876-019-0992-2.

Related content

Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study

Vedolizumab Efficacy, Safety, and Pharmacokinetics with Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients with Crohn's Disease or Ulcerative Colitis

Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn's Disease: Results from the Phase 2 Open-Label Extension Study

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease

Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial

Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn's Disease: A Post Hoc Analysis of GEMINI 2 and 3

Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis

Autologous stem cell transplantation in refractory Crohn's disease - low intensity therapy evaluation (ASTIClite): study protocols for a multicentre, randomised controlled trial and observational follow up study